RxDoctor Payments Data

Victoria Holiday, MD

Neurology · Louisville, KYNPI 1477879815

Payments from drug & device makers

$13,226in general payments, 2019–2025

Across 57 payments — averaging $232.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$8K
  • Medtronic$2K
  • Abbott$2K
  • Boston Scientific$756
  • MDD US Operations, LLC$265
  • Teva Pharmaceuticals USA, Inc.$125
  • plus $403 from 6 others

What the payments were for

  • Travel & lodging$3,08655%
  • Food & beverage$2,53945%
  • Education$281%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,226 in reported general payments places this provider in the 70th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$78,915
Medicare patients
301
Services billed
1,152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GocovriAmantadine Hcl55$185,788
Austedo XrDeutetrabenazine14$184,554
NuplazidPimavanserin Tartrate22$116,273
RytaryCarbidopa/Levodopa45$88,325
DuopaCarbidopa/Levodopa12$75,070
InbrijaLevodopa13$60,034
NourianzIstradefylline18$35,757
NeuproRotigotine12$20,447
Carbidopa-LevodopaCarbidopa/Levodopa441$19,193
Carbidopa-Levodopa ErCarbidopa/Levodopa99$10,958
Pramipexole ErPramipexole Di-Hcl17$7,364
Rasagiline Mesylate31$7,277
Entacapone42$6,445
AmantadineAmantadine Hcl69$3,813
RivastigmineRivastigmine Tartrate31$3,627

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$265$185,78855 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$125$184,55414 claims
Acadia Pharmaceuticals IncNuplazid$109$116,27322 claims
Amneal Pharmaceuticals LLCRytary$120$88,32545 claims
Kyowa Kirin, Inc.Nourianz$112$35,75718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 210 neurology providers in Kentucky.

Other neurology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →